Predictors of virological failure among people living with HIV receiving first line antiretroviral treatment in Myanmar: retrospective cohort analysis

Table 3 Adjusted hazard ratios for virological failure among complete cases with more than 6 months of first-line ART and at least one VL test and complete data on key variables (n = 8,308)

Variable	aHR*	95% CI	P-value
Female	0.89	0.76–1.04	0.147
Age at ART initiation > 19 years	0.66	0.53–0.83	< 0.001
Baseline CD4 500 cells/mL	1.23	0.96–1.59	0.094
Baseline tuberculosis	1.30	1.14–1.49	< 0.001
Married	0.90	0.76–1.06	0.187
Single	0.83	0.66–1.03	0.089
History of sex work	0.71	0.18–2.86	0.633
History of IDU	1.05	0.77–1.43	0.764
History of loss-to-follow-up	1.24	1.01–1.52	0.041
History of low viremia	1.60	1.42–1.81	< 0.001
Cumulative appointment delay > = 60 days	0.94	0.79–1.12	0.473
No history of changing ART regimen	1.37	1.07–1.76	0.012

*Adjusted Hazard Ratio adjusted for variables presented in the table and history of ever receiving following categories of regimens: zidovudine/lamivudine/emtricitabine + abacavir/tenofovir;stavudine/zidovudine + lamivudine/emtricitabine + efavirenz; stavudine/zidovudine + lamivudine/emtricitabine + nevirapine; tenofovir/abacavir + lamivudine/emtricitabine + efavirenz or tenofovir/abacavir + lamivudine/emtricitabine + nevirapine; and time being on ART < or > = 2 years since access to viral load monitoring 1 January 2009); interaction between sex work and gender and gender and being single included in the model

ISSN: 1742-6405